Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma

Abstract Introduction Bevacizumab has demonstrated activity in glioblastoma (GBM), but the true benefits and optimal dose‐schedule are debated. A lower dose‐schedule than standard‐dose bevacizumab (10 mg/kg 2‐weekly) might offer similar benefits with lower costs. At our Institution, patients are ran...

Full description

Saved in:
Bibliographic Details
Main Authors: Jack Patrick Gleeson, Fergus Keane, Niamh M. Keegan, Emin Mammadov, Emily Harrold, Abdullah Alhusaini, Jeffrey Harte, Austin Eakin‐Love, Philip J. O'Halloran, Stephen MacNally, Bryan T. Hennessy, Oscar S. Breathnach, Liam Grogan, Patrick G. Morris
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Cancer Medicine
Subjects:
bevacizumab
cost analysis
glioblastoma
MGMT
overall survival
reduced dose
Online Access:https://doi.org/10.1002/cam4.2616
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.2616

Similar Items